Phase 2 N=32 Sequential Vaccinations in Prostate Cancer Patients
Prostatic Neoplasms
Primary: Number of Participants With an Immune Response — 2; 4; 4; 3 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=619 S9917, Selenium in Preventing Cancer in Patients With Neoplasia of the Prostate
Precancerous/Nonmalignant Condition · Prostate Cancer
Primary: Presence of Carcinoma of the Prostate as Measured by Biopsy — 48; 49 participants — p=0.73
Phase 2 N=40 Positron Emission Tomography and Magnetic Resonance Imaging for Prostate Cancer
Prostate Cancer
Primary: Compare the Biodistribution of 11C-acetate Positron Emission Tomography (PET)/Computed Tomography (CT) Imaging in Tumor and Non Tumorous Regions of the Prostate — 4.4…
Phase 2 N=39 Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate Cancer
Prostate Cancer
Primary: Median Tumor Volume Burden at Baseline Multi-parametric Magnetic Resonance Imaging (mpMRI) Before and After Surgery — 3.44; 0.62 cc
Phase 2 N=35 Maximal Suppression of the Androgen Axis in Clinically Localized Prostate Cancer
Cancer · Prostate Neoplasms
Primary: Prostate Tissue DHT — 0.03; 0.06; 0.03 ng/g
Phase 2 N=27 Ibrutinib as Neoadjuvant Therapy in Localized Prostate Cancer
Prostate Cancer
Primary: Number of Participants With Dose Limiting Toxicities (Phase I and Safety Run-In) — 0; 0 Participants
N/A N=130 Evaluation of Diagnostic Value of 3-T Magnetic Resonance Imaging (MRI) in Suspected Prostate Cancer
Prostatic Neoplasms
Primary: Number of Prostate Cancer Diagnoses in MRI and no MRI Groups — 34; 34 participants
Phase 2 N=51 The Role of 68Ga-PSMA-11 PET (Prostate Specific Membrane Antigen) in Surgery Guidance in Prostate Cancer
Prostate Cancer
Primary: Sensitivity of PSMA-PET and MRI Imaging Preoperatively for Predicting Extra-prostatic Extension — 86; 57 percentage — p=<0.05
Phase 2 N=40 PS-341 Followed by Removal of Prostate for Those With Prostate Cancer
Prostate Neoplasms
Primary: The Purpose of the Present Study is to Assess the Safety of PS-341 as a Pretreatment in Patients Who Are to Undergo a Radical Prostatectomy. Poor Wound Healing and…
Phase 3 N=122 68Ga-RM2 PET/MRI in Biochemically Recurrent Prostate Cancer
Prostate Adenocarcinoma
Primary: Number of Tumor Lesions Detected by 68Ga-RM2 MRI vs 68Ga-RM2 PET/MRI — 92; 127 number of tumor lesions
Phase 2 N=8 Nivolumab in Biochemically Recurrent dMMR Prostate Cancer
Prostate Cancer · Recurrent Prostate Cancer
Primary: Percentage of Participants With PSA50 Response — 2 Participants
N/A N=25 MRI- Guided Transurethral Ultrasound Ablation of Localized Prostate Cancer
MRI Guided Transurethral Ultrasound Ablation · Localized Prostate Cancer · Ablation Therapy
Primary: Absence of Clinically Significant Cancer (CSC) on Control Biopsy at 1-year Follow-up. — 8 Participants
Phase 2 N=118 Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide Prostate Cancer Undergoing Prostatectomy
Prostate Cancer
Primary: Combined pCR or MRD Rate [Part 1] — 12; 12 Participants
Phase 2 N=75 Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate
Prostate Adenocarcinoma · Prostate Cancer · High Risk Prostate Cancer
Primary: Percentage of Participants With Pathologic Complete Response (pCR) or Minimal Residual Disease (MRD) — 30; 16 percentage of participants — p=0.151
Phase 2 N=28 Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer
Newly Diagnosed Oligometastatic Prostate Cancer
Primary: Percentage of Participants With PSA<0.05ng/mL (Radical Prostatectomy) or PSA <Nadir+2ng/mL (Prostate Radiation) — 20 Participants
Phase 2 N=24 PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer
Prostate Cancer
Primary: Number of Participants With Clinically Important Immune-related Adverse Events (for the Lead-In Cohort) — 1; 1; 1; 1 Participants
N/A N=22 PRAGMA (Prostate Radio Ablation Guided by Magnetic Resonance Imaging Acquisition) in Metastatic Prostate Cancer
Metastatic Prostate Cancer
Primary: Change in Number of Subjects With Adverse Events Will be Collected — 22; 18; 17 Participants
Phase 2 N=80 Prostvac in Patients With Biochemically Recurrent Prostate Cancer
Prostate Cancer
Primary: Tumor Growth Rate as Measured by Prostate-specific Antigen (PSA) Rise After 6 Months When PROSTVAC is Initiated Compared to a Group on Surveillance for 6 Months…
N/A N=24 Detection of Clinically Significant Prostate Cancer Using Transperineal Targeted Biopsy Compared to Standard Transrectal Biopsy
Prostate Cancer · Magnetic Resonance Imaging · Target Lesion
Primary: Number of Participants With Clinically Significant Prostate Cancer — 6; 6 Participants
Phase 2 N=1 Efficacy Trial of the Implantation of Mouse Renal Adenocarcinoma Macrobeads in Subjects With Castration-Resistant Prostate Cancer Resistant to Taxanes (Docetaxel, Cabazitaxel) and Evidence of Disease Progression on Androgen-axis Inhibition and/or Immunotherapy in the Form of Sipuleucel-T
Prostate Cancer
Primary: Overall Survival
Phase 2 N=16 Trial of NanoPac® Focal Therapy in Subjects With Prostate Cancer
Adenocarcinoma of the Prostate
Primary: Number of Participants With Treatment Emergent Adverse Events (Safety and Tolerability) — 3; 2; 6; 3 Participants
Phase 2 N=42 Sipuleucel-T as Neoadjuvant Treatment in Prostate Cancer
Prostate Cancer
Primary: Change in the Number of Infiltrating CD3+ T Cells Within the Prostate Tissue Between the Biopsy and the Post-RP Tissue Specimens in Each Subject — 2.33; 2.03; 1.98; 6.39…
N/A N=95 Predicting Location and Extent of Prostate Cancer Using Micro-Ultrasound Imaging
Prostate Cancer
Primary: Micro-Ultrasound Detection of High Grade Prostate Cancer (Gleason Score ≥7) vs. Surgical Pathology — 38; 50 participants
N/A N=1,953 Prostate Cancer - Comparative Outcomes of New Conceptual Paradigms for Treatment
Prostate Cancer
Primary: Assessing Percentage of Participants Who Reported Adverse Events Following Treatment by Common Terminology Criteria for Adverse Events (CTCAE) v5.0 — 4.1; 4.3; 4.1; 10…
N/A N=9 Urology of Virginia Case Series
Prostate Cancer · Cancer of the PROSTATE · Prostatic Neoplasm
Primary: Keyword Description of Each Biopsy Sample — 89 percentage significant cancers detected
Phase 2 N=30 Pomegranate-Extract Pill in Preventing Tumor Growth in Patients With Localized Prostate Cancer Undergoing Active Surveillance
PSA Level Less Than or Equal to Fifteen · PSA Level Less Than Ten · Stage I Prostate Cancer AJCC v7
Primary: Change in Plasma IGF-1 From Baseline to Post-Treatment — 19.12; 8.54 ng/mL — p=0.190
Phase 2 N=154 PROSTVAC (PSA-TRICOM) in Preventing Disease Progression in Patients With Localized Prostate Cancer Undergoing Active Surveillance
Stage I Prostate Adenocarcinoma AJCC v7 · Stage II Prostate Adenocarcinoma AJCC v7
Primary: Change in CD8+ Positive Cells in the Stroma Adjacent to Tumor and Within the Malignant Portion of the Prostate Biopsies — 12.2; -6.9 number of positive cells per mm^2
Phase 2 N=13 Evaluation of Prostate-specific Membrane Antigen (PSMA)-Based PET Imaging of Primary Prostate Cancer
Prostate Cancer
Primary: PET Detection of Primary Prostate Cancer — 6; 7 Participants
Early Phase 1 N=19 Intensity Modulated Radiation Therapy for Prostate Cancer
Prostate Cancer
Primary: Number of Participants With Any Grade 2 Toxicity Using Intensity Modulated Radiation Therapy (IMRT) to Treat the At-risk Lymph Nodes in Prostate Cancer ( up to First 10…
Phase 2 N=27 Gallium Ga 68 DOTA-NeoBOMB1 and Gallium Ga 68 PSMA-R2 PET/MRI in Diagnosing Participants With Recurrent Prostate Cancer
Prostate Adenocarcinoma · PSA Progression · Recurrent Prostate Carcinoma
Primary: Number of Lesions Detected by Investigational Imaging Agent — 31; 20 lesions